Search for: "SANDOZ, INC."
Results 461 - 480
of 679
Sorted by Relevance
|
Sort by Date
30 Jun 2010, 5:52 am
Sandoz Inc. [read post]
27 May 2010, 3:40 pm
Richardson-Merrell, Inc., 649 F. [read post]
22 Sep 2022, 9:54 am
Sandoz, which produces a biosimilar sold outside of the US called Erelzi, attempted to invalidate the patents, taking their case all the way to the Supreme Court (Sandoz Inc. v Immunex Corp., 20-1110, Supreme Court). [read post]
14 Nov 2016, 9:16 am
Lexmark International, Inc., No. 15-1189 (unreasonable restraints on downstream uses) BPCIA – Notice of Commercial Marketing: Sandoz Inc. v. [read post]
10 Jun 2010, 1:40 pm
Sandoz, Inc., 544 F.3d 1341 (Fed. [read post]
14 Jan 2023, 9:33 am
Here is how Judge Henderson opened her opinion (joined by Judges Walker and Sentelle): Finally, we have Sandoz Inc. v. [read post]
25 Feb 2009, 12:50 am
Sandoz Inc.U.S. [read post]
5 Jan 2009, 6:32 pm
Affected by the FDA recall are Duragesic 50 mcg/hr patches in lot number 0817239 as are Sandoz Inc. 50 mcg/hr patches in lot number 0816851. [read post]
24 Dec 2008, 3:00 pm
Apotex, Inc (Managing Intellectual Property) [read post]
9 Mar 2016, 11:43 am
Sandoz, Inc., 135 S. [read post]
14 Mar 2014, 8:00 am
Sandoz, Inc., 13-854, a patent-infringement suit over a drug widely prescribed for treating multiple sclerosis, and a case so well-lawyered that Alan Dershowitz’s name appears on the brief’s inside cover. [read post]
28 Sep 2016, 8:39 am
Lexmark International, Inc., No. 15-1189 (unreasonable restraints on downstream uses) BPCIA – Notice of Commercial Marketing: Sandoz Inc. v. [read post]
13 Oct 2016, 6:50 am
Lexmark International, Inc., No. 15-1189 (unreasonable restraints on downstream uses) BPCIA – Notice of Commercial Marketing: Sandoz Inc. v. [read post]
14 Dec 2009, 4:38 pm
Sandoz, Inc. [read post]
31 Aug 2015, 7:52 am
See Litton Sys., Inc. v. [read post]
19 May 2010, 6:15 am
Immutopics, Inc. [read post]
23 Jan 2019, 8:23 am
” Gilead Scis., Inc. v. [read post]
19 Apr 2014, 8:50 am
On Good Friday, April 18, 2014, Chief Justice Roberts, denied Teva a request for a stay in the Copaxone case, noting that he was not convinced Teva had shown the "likelihood of irreparable harm" if the application was denied, because if Teva wins the Supreme Court case it can seek damages from the generic companies for past infringement on its patents.In this case, Teva, a known generic manufacturer, is in the role of proprietary drug maker, fighting the generic arm of a proprietary company… [read post]
21 Jul 2010, 1:05 am
Lupin Pharmaceuticals, Inc (FDA Law Blog) Olux (Clobetasol) – Perrigo confirms patent challenge for Colobetasol propionate emulsion foam (GenericsWeb) Prandin (Repaglinide) – US: Actavis, Sandoz bring inequitable conduct counterclaims against Novo Nordisk in Prandin suit (Patent Docs) Protonix (Pantoprazole) – US: District Court New Jersey denies Teva’s motion to overturn jury verdict finding the patent in suit not invalid in Protonix litigation (SmartBrief)… [read post]
31 Mar 2014, 6:56 am
ABC, Inc., v. [read post]
